FLT3 Gene Mutation Quantitative Monitor Test
Comprehensive Introduction to FLT3 Gene Mutation Testing
The FLT3 Gene Mutation Quantitative Monitor Test represents a breakthrough in molecular diagnostics for leukemia management. This sophisticated test utilizes real-time PCR technology to detect and quantify FLT3 (FMS-like tyrosine kinase 3) gene mutations, which play a critical role in the development and progression of acute myeloid leukemia (AML). FLT3 mutations are among the most common genetic abnormalities found in AML patients, affecting approximately 30% of cases and significantly influencing treatment decisions and prognosis.
Understanding FLT3 mutation status has become essential in modern hematology practice, as these mutations drive uncontrolled cell proliferation and are associated with poorer clinical outcomes. The quantitative nature of this test provides healthcare providers with precise measurements of mutation burden, enabling more accurate risk stratification and personalized treatment approaches.
What the FLT3 Mutation Test Measures and Detects
This advanced molecular test specifically targets and quantifies two primary types of FLT3 mutations:
FLT3-ITD (Internal Tandem Duplication) Mutations
- Detects internal tandem duplications in the juxtamembrane domain
- Quantifies the mutation burden percentage
- Identifies the specific length and position of duplications
- Measures allelic ratio for prognostic assessment
FLT3-TKD (Tyrosine Kinase Domain) Mutations
- Screens for point mutations in the activation loop
- Identifies specific amino acid substitutions
- Quantifies mutation levels for treatment monitoring
- Detects emerging resistance mutations during therapy
Who Should Consider FLT3 Gene Mutation Testing
This test is recommended for individuals in the following clinical scenarios:
Newly Diagnosed AML Patients
- All patients with newly diagnosed acute myeloid leukemia
- Individuals with suspected myeloid malignancies
- Patients with unexplained cytopenias or bone marrow abnormalities
Patients Undergoing Treatment
- Individuals receiving FLT3 inhibitor therapies
- Patients requiring treatment response assessment
- Those experiencing disease progression or relapse
Monitoring and Follow-up Cases
- Post-treatment minimal residual disease monitoring
- Patients in remission requiring surveillance
- Individuals with previous FLT3-positive AML
Significant Benefits of FLT3 Mutation Testing
Undergoing FLT3 gene mutation testing provides numerous clinical advantages:
Precision Treatment Selection
- Identifies candidates for FLT3 inhibitor therapies
- Enables targeted treatment approaches
- Helps avoid ineffective conventional chemotherapy
- Supports personalized medicine strategies
Accurate Prognostic Assessment
- Provides critical risk stratification information
- Helps predict treatment response and outcomes
- Supports informed clinical decision-making
- Enables appropriate intensity treatment planning
Comprehensive Disease Monitoring
- Quantitative tracking of mutation burden over time
- Early detection of treatment resistance
- Monitoring minimal residual disease status
- Guiding therapy modifications as needed
Understanding Your FLT3 Test Results
Interpreting FLT3 mutation test results requires careful consideration of multiple factors:
Positive Results Interpretation
- FLT3-ITD Positive: Indicates internal tandem duplication mutation present; higher allelic ratios generally correlate with poorer prognosis
- FLT3-TKD Positive: Suggests tyrosine kinase domain mutation; may influence response to specific inhibitors
- Quantitative Values: Mutation burden percentage helps determine treatment intensity and monitoring frequency
Negative Results Interpretation
- No Mutation Detected: Suggests standard risk category; may indicate better response to conventional chemotherapy
- Monitoring Context: In previously positive patients, negative results may indicate treatment response or complete remission
Clinical Correlation
- Results should always be interpreted in conjunction with other diagnostic findings
- Consultation with a hematologist is essential for comprehensive assessment
- Regular monitoring may be recommended based on initial results
Test Pricing and Scheduling Information
| Price Type | Amount (USD) |
|---|---|
| Discount Price | $112 |
| Regular Price | $162 |
Test Availability and Turnaround
- Sample Collection: Monday or Thursday by 11 AM
- Report Delivery: Wednesday or Saturday
- Sample Requirements: 5 mL (3 mL minimum) whole blood or bone marrow in Lavender Top (EDTA) tube
- Shipping Instructions: Refrigerated transport required; DO NOT FREEZE
- Mandatory Documentation: Duly filled MRD Requisition Form (Form 22) with historical data
Nationwide Availability and Booking
We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more cities nationwide. Our extensive network ensures accessible, high-quality molecular diagnostic services for patients requiring FLT3 mutation analysis.
Take Action Today
Don’t delay critical leukemia diagnostics. Our experienced team is ready to assist you with scheduling, sample collection, and result interpretation. Early detection and precise monitoring of FLT3 mutations can significantly impact treatment success and patient outcomes.
Call or WhatsApp us today at +1(267) 388-9828 to book your FLT3 Gene Mutation Quantitative Monitor Test and take the first step toward personalized leukemia management.
Our dedicated hematology specialists and molecular diagnostics team are committed to providing accurate, timely results that empower you and your healthcare provider to make informed treatment decisions. Trust our expertise in leukemia genetics and benefit from our affordable pricing and nationwide accessibility.
